CHRS Coherus BioSciences, Inc.
$0.41
Coherus BioSciences, Inc. (CHRS) Earnings News
Earnings press releases, previews and reviews for Coherus BioSciences, Inc. (CHRS), newest first. Our most recent is review: Coherus Misses on Both Lines as Loqtorzi Stalls, Guidance Is Cut and a Going-Concern Warning Overshadows an Esophageal Signal.
Monday
November 9, 2026
6:58 PM ET
Coherus Misses on Both Lines as Loqtorzi Stalls, Guidance Is Cut and a Going-Concern Warning Overshadows an Esophageal Signal
Earnings Whispers · Review
Monday
November 9, 2026
4:06 PM ET
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
Monday
November 2, 2026
6:25 PM ET
Coherus Needs Loctorsi Growth and a Udenica Milestone to Steady a Sub-Dollar Stock
Earnings Whispers · Preview
Monday
October 26, 2026
9:30 AM ET
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Wednesday
August 5, 2026
4:28 PM ET
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Wednesday
July 22, 2026
1:36 PM ET
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026